Human papilloma virus (HPV) is the most common sexually transmitted viral disease responsible for mucosal warts and anogenital malignancies. HPV-associated oral lesions include condyloma, focal epithelial hyperplasia and some squamous cell carcinomas. Recent studies have shown an increased risk of oral warts in HIV positive individuals. This article, reports an unusual presentation of a disseminated oral HPV infection in a newly diagnosed HIV positive patient after the initiation of highly active antiretrovirals therapy (HAART).
A 22 year old African-American male presented to the clinic for evaluation of multiple oral lesions (Fig. 1) . The patient was recently diagnosed with HIV (four months) and was started on the highly active antiretroviral drug therapy. He first noticed the lesions on his lips three weeks after starting his antiretroviral medications (Fig. 2) . Intraoral exam examination revealed multiple papillary raised lesions measuring 0.2-0.8 cm in diameter disseminated intra-orally on the labial and buccal mucosa (Figs. [2] [3] [4] [5] [6] . There were no other oral lesions, tumors or masses noted intraorally. Review of systems was unremarkable with no otalgia, dysphagia, odynophagia, hoarseness or coughing. The patient's extra oral exam revealed a normocephalic facial symmetry with no signs or symptoms of acute infection, swelling or tenderness. The patient did not have any other significant medical history. His CD4 count was 220 and the viral load was 20500. The patient was presently on a regimen of nevirapine (Viramune; Boehringer Ingelkeim Corporation, Connecticut, USA), Ritonavir (Kaletra; Abbott Laboratories, IL, USA), ABACAVIR (Ziagen; Glaxosmithkline, Munich, Germany) and efavirenz (Sustiva; Bristol Myers Squibb, Chicago, USA). There was no history of tobacco, alcohol or illicit drug use. The patient agreed to undergo an incisional biopsy of the lesions on two different sites in the maxillary and mandibular region. The histologic examination revealed a benign papillary lesion consistent with a diagnosis of papilloma from each site biopsied. The patient was referred to the oral and maxillofacial surgery clinic for laser ablation of the papillary lesions. As with the HIV À population there are large differences between the infection rates with HPV and the occurrence of oral lesions, 2-4 however, these HPV-associated lesions occur more commonly under conditions of immune suppression. [5] [6] [7] In addition, oral lesions similar to those seen in HIV À individuals contain additional or novel HPV types in a significant subpopulation. (2.5-4% of HIV + patients). 6 Greenspan et al. have described cauliflower and spiky warts containing HPV type 7 and flat warts, similar in appearance to FEH, containing HPV 13, 18 and 32. 8, 9 A study of benign oral lesions, not restricted to warts, Volter et al. found HPV DNA sequences in 67% of the specimens. 3 The most common types found were HPV 32 (28%) and HPV 7 (19%), which would have been missed if testing only for genital HPV types. A study on oral squamous cell carcinomas in HIV + individuals have demonstrated an early age of onset, an aggressive course, and a high rate of HPV DNA detection. 10 Comparative studies have shown that HPV infection is increased in the HIV + individual as demonstrated by Coutlee et al. where HPV DNA was detected in 2.6% of the oral cavities of HIV À adults compared to 14.4% of the HIV + individu-als. 11 Again, only genital types of HPV were studied and no specific methods to detect non-genital types of HPV were attempted, which could lead to an underestimation of the HPV prevalence rates. Genital HPV infection is also increased in HIV + women compared to HIV À women with more women infected with multiple types of HPV, particularly high-risk HPV infections leading to anogenital malignancies. 12, 13 Women represent a growing percentage of the HIV + population and indeed the risk factors for oral HPV infection in HIV + women may differ from HIV + men, as may the rates of HPV-related oral disease. In addition, the genital tract could serve as a reservoir for current or future oral infection. Clearly, studies are needed to more fully examine the site of oral HPV infection as well as the genotype(s) involved.
The health of HIV-infected patients relies on the longterm control of HIV viral load and subsequent restoration of immunity. The most successful therapeutic approach to date has been a combination-drug approach known as highly active antiretroviral therapy (HAART). HAART typically consists of a cocktail of three drugs, two of which are nucleoside analogue reverse transcriptase (RT) inhibitors, and one of which is either a non-nucleoside RT inhibitor or a protease inhibitor (PI). A new class of drug namely the Fusion Inhibitors has been recently released as well. These drugs have been summarized in Table 1 . HAART has been responsible for decreasing HIV plasma viral loads, increasing CD4+ T lymphocyte counts, prolonging the progression to AIDS Disseminated oral HPV lesion eruptions after the initiation of antiretroviral therapy and decreasing the mortality from HIV. 5 HAART has also decreased the incidence of opportunistic infections, including those of the oral cavity. Since the administration of HAART therapy, the incidences of OPC and OHL have significantly decreased. 14 15 The reasons for the unexpected rise in incidence of oral warts remain unknown; the spectrum of possibilities includes epidemiological (e.g., an epidemic of oral HPV infections, or unknown epidemiological confounder that explains the observation), chemical (e.g., a direct impact of treatment regimens on host or virus), viral (interactions between HIV and HPV and/or changes in their ecological niches), and immunological (e.g., immune restoration disease, or a lack of restoration of an essential component of HPV immune control).
Conclusion
Human papilloma virus is a ubiquitous pathogen that infects mucosal surfaces especially the genital tract and oral cavity. The current clinical observation of an increase in oral pathology due to HPV in the HIV + individual in the setting of active anti-retroviral therapy implies the lack of mucosal immune reconstitution.
